Group 1 - The company reported a revenue of 38.027 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 49,285.71% [1] - The increase in revenue is primarily attributed to recent payments received under the licensing and collaboration agreement with Axion Bio, Inc. [1] - Research and development expenses amounted to 168 million RMB, reflecting a year-on-year increase of 41.05% [1] Group 2 - The rise in R&D expenses is due to several factors, including an increase of 43.4 million RMB in preclinical and CMC expenses, mainly related to the production and CDMO costs for clinical trials of IMM01, IMM2510, and IMM0306 [1] - Clinical trial expenses increased by 8.3 million RMB, primarily due to the ongoing clinical development of IMM01 and IMM2510 [1] - Salary and related benefits increased by 4.9 million RMB as the clinical team expanded, aligning with the company's ongoing efforts to advance and expand its drug pipeline [1]
宜明昂科-B(01541)发布中期业绩 收入3802.7万元 同比大幅增加49285.71%